[1]Kannel WB.Range of serum cholesterol values in the population developing coronary artery disease\[J\].Am J Cardiol,1995,76(9): 69-77.
[2]Goodman DWS,Hulley SB,Clark LT,et al.Report of the national cholesterol education program expert panel on detection,evaluation,and treatment of high blood cholesterol in adults\[J\].Arch Intern Med,1988,148(1):36-69.
[3]Castelli WP.Epidemiology of coronary heart disease:the Framingham study\[J\].Am J Med, 1984, 76(2): 4-12.
[4]Pedersen TR,Kjekshus J,Berg K,et al.Randomised trial of cholesterol lowering in 4444 subjects with coronary heart disease:the scandinavian simvastatin survival study(4S) \[J\].Lancet,1994,344(8934):1383-1389.
[5]Shepherd J,Cobbe SM,Ford I,et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiawest of scotland coronary prevention study group\[J\].N Engl J Med,1995,333(20):1301-1307.
[6]The longterm intervention with pravastatin in ischemic disease (LIPID) study group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels\[J\].N Engl J Med,1998,339(19):1349-1357.
[7]Ridker PM,Rifai N,Pfeffer MA,et al.Longterm effects of pravastatin on plasma concentration of creactive proteinthe cholesterol and recurrent events (CARE) investigators\[J\].Circulation,1999,100(3):230-235.
[8]Downs JR,Clearfield M,Weis S,et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPSair force/texas coronary atherosclerosis prevention study\[J\].JAMA,1998,279(20):1615-1622.
[9]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南\[J\].中华心血管病杂志,2007,35(5):390-419.
[10]中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)\[J\].中华心血管病杂志,2016,44(10):833-853.
[11]孙英贤. 胆固醇吸收抑制剂的临床应用\[J\].中国实用内科杂志,2009,29(1):14-17.
[12]陈晓兵.阿托伐他汀联合苯扎贝特对急性冠脉综合征的疗效\[J\].河南医学研究,2019,28(1):126-128.
[13]The ACCORD Study Group.Effects of combination lipid therapy in type 2 diabetes mellitus\[J\].N Engl J Med,2010,362(17):1563-1574.
[14]Choi HD, Shin WG.Safety and efficacy of statin treatment alone and in combination with fibratus in patients with dyslipidemia: a metaanalysis\[J\].Curr Med Res Opin,2014,30(1):1-10.
[15]2014年中国胆固醇教育计划血脂异常防治建议专家组.2014年中国胆固醇教育计划血脂异常防治专家建议\[J\].全科医学临床与教育,2015,13(1):3-5.
[16]中国胆固醇教育专家委员会.选择性胆固醇吸收抑制剂临床应用中国专家共识(2015)\[J\].浙江医学,2015,37(16):1335-1339,1356.
[17]Xie P,Jai L,Ma Y,et al.Ezetimibe inhibits hepatic NiemannPick C1Like 1 to facilitate macrophage reverse cholesterol transport in mice\[J\].Arterioscler Thromb Vasc Biol,2013,33(5):920-925.
[18]Stein EA.Managing dyslipidemia in the highrisk patient\[J\].Am J Cardiol,2002,89(5):50-57.
[19]Rosseb AB,Pedersen TR,Boman K,et al.Intensive lipid lowering with simvastain and ezetimibe in aortic stenosis\[J\].N Engl J Med,2008,359(13):1343-1356.
[20]SHARP Collaborative Group.Study of heart and renal protection(SHARP):randomized trail to assess the effects of lowering lowdensity lipoprotein cholesterol among 9438 patients with chronic kidney disease\[J\].Am Heart J,2010,160(5):785-794.
[21]Cannon CP, Blazing MA, Giugliano RP. Ezetimibe added to statin therapy after acute coronary syndromes\[J\].N Engl J Med,2015,372(25):2387-2397.
[22]刘壮,耿雪梅,柯永胜.PCSK9抑制剂在脂代谢中的研究进展\[J\].大连医科大学学报,2019,41(1):81-85.
[23]Robinson JG,Rosenson RS,Farnier M,et al.Safety of very lowdensity lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials\[J\].J Am Coll Cardiol,2017,69(5):471-482.
[24]Sabatine MS,Giugliano RP,Keech AC,et al.Evolocumab and clinical outcomes in patients with cardiovascular disease\[J\].N Engl J Med,2017,376(18):1713-1722.
[25]Sabatine MS,De Ferrari GM,Giugliano RP,et al.Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER\[J\].Circulation,2018,138(8):756-766.
[26]Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association to force on clinical practice guidelines\[J\].J Am Coll Cardiol,2019,73(24):285-350.
[27]Mach F, Baigent C, Catapano AL, et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification of reduce cardiovascular risk\[J\].Eur Heart J,2020,41(1):111-188. |